海正药业：挂牌转让浙江省医药工业有限公司100%股权

Core Viewpoint - Haizheng Pharmaceutical (600267) has submitted an application for the transfer of 100% equity of its wholly-owned subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd., to the Taizhou Property Rights Exchange, marking a significant step in its strategic restructuring [1] Group 1 - The application for the equity transfer was submitted on November 10, 2023 [1] - The official listing period for the equity transfer is from November 11, 2025, to December 8, 2025 [1]